Diethylstilbestrol monobenzyl ether

Diethylstilbestrol monobenzyl ether (DESMBE), also known as benzestrol, is a synthetic, nonsteroidal estrogen that was studied for medical use but was never marketed. It is a derivative of diethylstilbestrol (DES), a well-known synthetic estrogen that has been widely used in the past for various medical conditions, including hormonal replacement therapy and in efforts to prevent miscarriages. DESMBE, like its parent compound DES, acts as an estrogen receptor agonist, binding to estrogen receptors and mimicking the action of the natural hormone estrogen in the body.
History[edit]
The development of DESMBE traces back to the early 20th century when researchers were actively seeking synthetic estrogens that could be used for therapeutic purposes. Diethylstilbestrol itself was first synthesized in 1938 and quickly found a variety of medical applications. Following the discovery of DES, scientists experimented with various derivatives, including DESMBE, in search of compounds with improved efficacy, safety, or pharmacokinetic properties.
Pharmacology[edit]
DESMBE, like other estrogens, exerts its effects by binding to estrogen receptors in target tissues, which include the reproductive organs, breast, bone, and cardiovascular system. Upon binding to these receptors, DESMBE initiates a series of cellular events leading to the transcription of specific genes and the subsequent production of proteins that are responsible for the development and maintenance of female secondary sexual characteristics, as well as other physiological effects associated with estrogen.
Clinical Uses[edit]
Although DESMBE was studied for potential medical applications, it was never approved for use in any country. Research into its efficacy and safety was likely overshadowed by the widespread adoption of DES and later concerns about the adverse effects associated with DES use, such as an increased risk of certain cancers in both the mothers who took DES and their offspring.
Adverse Effects[edit]
Given that DESMBE is a derivative of DES, it is plausible that its use could have led to similar adverse effects as those observed with DES, including an increased risk of cancers such as clear cell adenocarcinoma of the vagina and cervix in daughters exposed in utero, as well as potential cardiovascular and reproductive issues. However, without widespread use, specific adverse effects of DESMBE remain speculative.
Current Status[edit]
Today, DESMBE is of interest primarily for its historical significance in the development of synthetic estrogens. The lessons learned from the use and study of DES and its derivatives have informed the development of safer and more effective estrogenic compounds for medical use.
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99 with insurance
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
